Trial Profile

Phase I/II study of Nivolumab plus Lenvatinib for advanced biliary tract cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Biliary cancer
Focus Adverse reactions; Therapeutic Use
Acronyms SNIPE

Most Recent Events

18 Oct 2022 Status changed from suspended to completed.
13 Sep 2022 Results (n=32) assessing efficacy and safety of nivolumab plus lenvatinib in second-line treatment for advanced biliary tract cancer patients, presented at the 47th European Society for Medical Oncology Congress.
20 Jan 2021 Status changed from recruiting to suspended due to completion of Phase II part registration.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com